Featured Articles

1. From LNP Delivery To Functional CAR-T: Rethinking Targeting 10/16/2026

   Optimizing LNPs for in vivo CAR-T requires aligning target selection, formulation design, and delivery performance to achieve functional CAR expression in desired T-cell populations while balancing specificity, safety, dosing flexibility, and manufacturability.

2. Top 5 Things To Know About The Lipid Nanoparticle Portfolio 10/13/2026

   Lipids that shift charge with pH can be chosen to fit the application and delivery route. Varied pKa and biodegradability give developers room to match each therapeutic target.

3. Expand mRNA-LNP Nanomedicine Potential By Optimizing Lipids 10/13/2026

   Ionizable lipid selection ratios shape how well lipid nanoparticles deliver nucleic acids, and empirical testing shows that similar physical properties can still produce very different performance.

4. Enabling Effective Passive And Active Immune Cell Targeting Strategies 8/10/2026

   Targeted LNPs that bypass the liver and home to the spleen could reshape in vivo CAR T cell manufacturing. See the data behind the approach.

5. Developing Non-PEG Stabilizer Lipids For Nucleic Acid Lipid Nanoparticles 7/1/2026

   Non-PEG stabilizer lipids may offer a new path for LNP design. Combining strong colloidal performance with greater chemical flexibility helps address growing concerns around PEG-related immunogenicity.

6. Neoantigen-Based Personalized Cancer Vaccine 7/1/2026

   Personalized cancer vaccines are advancing quickly, but effective delivery remains a major hurdle. Learn how mRNA and lipid nanoparticle design influence targeting, endosomal escape, and repeat dosing.

7. Lipid Nanoparticles For Pulmonary Delivery Of mRNA 7/1/2026

   Gain insight into how nebulized mRNA lipid nanoparticles show preclinical success in lung delivery, offering fresh momentum for inhaled gene therapies targeting respiratory diseases.

8. LNP-Mediated Cell Transfection In Bioreactors Across Workflows 6/24/2026

   Lipid nanoparticles are redefining immune cell engineering. Delve into new data that demonstrates the performance across multiple cell types and bioreactor systems, supporting their potential workflows.

9. Towards A Universal LNP Platform For Multiplex Engineering 6/19/2026

   Multiplex engineering of T cells for solid tumors requires precise delivery. Emerging LNP approaches enable co-delivery of RNA and DNA, offering a safer, more scalable path beyond viral vectors.

10. Extrahepatic Delivery Of mRNA-LNP To Spleen 6/19/2026

    In vivo CAR-T approaches aim to reprogram T cells directly in the body using targeted lipid nanoparticles. Improved delivery to immune organs highlights new potential for scalable cell therapies.